Frey's syndrome and botulinum toxin type A: duration of efficacy and patient satisfaction

Dessart, P.; Truchot, E.; Maillard, H.

doi:10.1111/jdv.13079

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Dessart claimed that the injection of BTXA is the first‐line treatment of FS . However, Li and his colleagues declared that they were unable to establish the efficacy and safety for the treatment of FS because lacking of RCTs .…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles

Xie

Wang

et al. 2015

Cancer Medicine

View full text Add to dashboard Cite

Frey’s syndrome (FS) is an unavoidable sequela following the surgery of the parotid gland. Although several treatment methods are available, their efficacy is short term or accompanied by unacceptable complications. In the past two decades, botulinum toxin type A (BTXA) has been widely used to treat FS. Although several systematic reviews have been reported recently, they were conflicting and with obvious deficiencies. Thus, we performed an objectively systematic review to determine whether BTXA is an effective and safe treatment for FS. A literature retrieval covering PubMed, Web of Science, Ovid, Embase and Cochrane library was performed on 16 January, 2015. Proportion meta-analysis and corresponding 95% confidence interval (CI) were performed to evaluate the efficacy and safety of BXTA in treatment of FS. A total of 499 records were retrieved and 22 articles with 23 studies were included after scrutiny by two independent authors. Statistical analyses regarding the effective rate, incidence of complications were used to estimate the efficacy and safety of BTXA. Our results suggested that the effective rate of BTXA for treatment of FS is 98.5% (95% CI = 0.971–0.994) and the incidence of complication is 3.6% (95% CI = 0.017–0.061). In conclusion, our study supports that BTXA produces meaningful benefits on the treatment of patients with FS. However, owing to lack of strong evidence, future studies with well-designed inclusion criteria and multicenter randomized controlled trials are needed to give more credible evidence, if possible.

show abstract

Section: Discussionmentioning

confidence: 99%